Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

This study has been completed.
Sponsor:
Collaborator:
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00288626
First received: February 7, 2006
Last updated: January 12, 2016
Last verified: January 2016